New monkeypox vaccine enters human testing
NCT ID NCT06771479
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new vaccine against monkeypox in 120 healthy adults aged 18 and older. Participants will receive two doses of either a low or high dose of the MVA strain live vaccine, or a placebo. The study aims to check if the vaccine is safe and whether it triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MVA strain monkeypox attenuated live vaccine
- What this could lead to
- If successful, this could lead to a safe and effective vaccine to prevent monkeypox infection.
- What could go wrong
- This is an early Phase 1 trial with only 120 participants, so safety and immune response are still being tested. The vaccine may not produce strong enough immunity or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Infectious Disease Hospital
RECRUITINGZhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smallpox vaccine stop mpox in its tracks?
- Experimental drug targets smallpox and monkeypox after exposure
- Monkeypox vaccine immune response under the microscope
- Can a pill speed up monkeypox recovery? major trial underway
- Scientists investigate mpox in severely weakened immune systems
- Could a smaller dose of monkeypox vaccine work just as well?